Pluri Inc (PLUR)
$5.25
+0.06
(+1.16%)▲
Performance
- $5.18$5.25$5.25
1.33%
Downside
Day's Volatility :1.33%
Upside
0.0%
- $3.45$8.48$5.25
34.31%
Downside
52 Weeks Volatility :59.33%
Upside
38.09%
Returns
| Period | Pluri Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -1.09% | 0.0% |
6 Months | -29.67% | 0.0% |
1 Year | 8.13% | 0.0% |
3 Years | -29.78% | -20.6% |
Highlights
Market Capitalization | 29.4M |
Book Value | - $0.07 |
Earnings Per Share (EPS) | -4.12 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -7794.37% |
Return On Assets TTM | -30.59% |
Return On Equity TTM | -194.38% |
Revenue TTM | 341.0K |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | -18.4% |
Gross Profit TTM | 278.0K |
EBITDA | -22.4M |
Diluted Eps TTM | -4.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.33 |
EPS Estimate Next Year | 0.42 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 23.81%
Technicals Summary
Sell
Neutral
Buy
Pluri Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pluri Inc | 1.68% | -29.67% | 8.13% | -29.78% | -29.78% |
 Regeneron Pharmaceuticals, Inc. | 0.93% | 17.32% | 35.75% | 73.95% | 298.81% |
 Novo Nordisk A/s | 0.96% | -0.08% | 31.44% | 163.47% | 428.79% |
 Alnylam Pharmaceuticals, Inc. | -8.66% | 65.51% | 21.14% | 30.19% | 192.84% |
 Vertex Pharmaceuticals Incorporated | 0.75% | 12.92% | 34.78% | 148.18% | 173.67% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pluri Inc | NA | NA | NA | -0.33 | -1.94 | -0.31 | NA | -0.07 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pluri Inc | Buy | $29.4M | -29.78% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 298.81% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 428.79% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 192.84% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 173.67% | 32.84 | -4.74% |
Insights on Pluri Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 105.0K → 71.0K (in $), with an average decrease of 32.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, 279.0K → -5.29M (in $), with an average decrease of 948.0% per quarter
Vs VRTX
In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 22.9%
Institutional Holdings
Values First Advisors Inc
0.27%Zurcher Kantonalbank
0.04%
Company Information
pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi
Organization | Pluri Inc |
Employees | 123 |
CEO | Mr. Yaacov Yanay |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$5.25
+1.16%
Keyarch Acquisition Corp
$5.25
+1.16%
Connexa Sports Technologies Inc
$5.25
+1.16%
Us Value Etf
$5.25
+1.16%
First Wave Biopharma Inc
$5.25
+1.16%
Global X Msci Next Emerging
$5.25
+1.16%
Fat Projects Acquisition Corp
$5.25
+1.16%
Capital Link Global Fintech
$5.25
+1.16%
Applied Uv Inc
$5.25
+1.16%